New hope for tough bladder cancer: immune drug plus chemo combo enters trial
NCT ID NCT07189793
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding chemotherapy drugs (gemcitabine and mitomycin C) directly into the bladder alongside an immune-boosting drug (toripalimab) works better than toripalimab alone for people with a high-risk bladder cancer that did not respond to standard BCG therapy. About 106 adults will be randomly assigned to one of two groups. The main goals are to see if the cancer disappears at 3 months (for those with a certain type) and how long it stays away. The trial is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (a drug that helps the immune system fight cancer) and a combination of gemcitabine and mitomycin C (chemotherapy drugs placed directly into the bladder)
What this could lead to
If successful, this could offer a new treatment option for people with bladder cancer that has not responded to standard therapy, potentially delaying or preventing cancer recurrence.
What could go wrong
This is an early-phase (Phase 2) trial with only 106 participants, so results may not apply to everyone. The combination therapy may cause side effects like bladder irritation or immune-related reactions, and it is not yet known if it works better than toripalimab alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••